Drug Profile
Resatorvid - Akaza Biopharma
Alternative Names: Compound(R)-(+)-5n; TAK 242; TAK-242 nanoparticle; TAK-242-NPLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Akaza Bioscience
- Developer Akaza Bioscience; Yaqrit
- Class Anti-inflammatories; Small molecules; Sulfonamides
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholic hepatitis; Liver failure
- Preclinical Hyperammonaemia; Inborn urea cycle disorders
- Discontinued Septic shock
Most Recent Events
- 16 Aug 2023 Pharmacodynamics data from preclinical studies in Hyperammonaemia presented at the European Association for the Study of the Liver Congress 2023
- 28 May 2020 Phase-II clinical trials in Liver failure in United Kingdom (IV) (EudraCT2019-001969-33)
- 20 Feb 2009 Discontinued - Phase-III for Septic shock in Europe (SC)